Levamisole Export Market Intelligence: India's 72 Suppliers Shipping to 39 Countries — TransData Nexus 2026

Q: Who are the top levamisole exporters from India?

The top levamisole exporters from India are: 1. LYKA BDR INTERNATIONAL LIMITED — $658.4K (24.7% market share); 2. LYKA LABS LIMITED — $387.4K (14.6% market share); 3. COMBITIC GLOBAL CAPLET PRIVATE LIMITED — $367.2K (13.8% market share); 4. DOSCH PHARMACEUTICALS PRIVATE LIMITED — $184.9K (6.9% market share); 5. PRASHI PHARMA PRIVATE LIMITED — $163.3K (6.1% market share). Together they account for 66.2% of India's total levamisole export value.

Q: What is the total export value of levamisole from India?

The total export value of levamisole from India is $2.7M USD, recorded across 325 shipment transactions from 72 active exporters to 39 destination countries. The average shipment value is $8.2K.

Q: Which countries import levamisole from India?

India exports levamisole to 39 countries worldwide. The top importing countries are: SUDAN (39.3% share, $1.0M), CONGO DR (14.9% share, $397.6K), UZBEKISTAN (14.0% share, $372.7K), UNITED KINGDOM (3.6% share, $95.5K), CHAD (3.1% share, $82.1K). These five markets account for 74.9% of total export value.

Q: What is the HS code for levamisole exports from India?

The primary HS code for levamisole exports from India is 30049099. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) for tracking and reporting pharmaceutical trade flows.

Q: What is the average price of levamisole exports from India?

The average unit price for levamisole exports from India is $7.36 USD per unit, with prices ranging from $0.00 to $284.46 depending on formulation, packaging, and order volume. The total market is valued at $2.7M across 325 shipments.

Q: Which ports handle levamisole exports from India?

The primary ports for levamisole exports from India are SAHAR AIR (18.2% of shipments), NHAVA SHEVA SEA (INNSA1) (16.6% of shipments), SAHAR AIR CARGO ACC (INBOM4) (11.4% of shipments), JNPT/ NHAVA SHEVA SEA (6.5% of shipments), JNPT (5.8% of shipments). These ports have dedicated pharmaceutical cargo infrastructure ensuring cold-chain and regulatory compliance during transit.

Q: Why is India a leading exporter of levamisole?

India is one of the world's leading exporters of levamisole due to its large base of 72 WHO-GMP and US FDA approved manufacturers, significantly lower production costs compared to Western markets, well-established API (Active Pharmaceutical Ingredient) supply chains, and strong government support for pharmaceutical exports through the Pharmaceuticals Export Promotion Council (Pharmexcil). India exports levamisole to 39 countries, demonstrating 20% global market coverage.

Q: What certifications do Indian levamisole exporters need?

Indian levamisole exporters typically require WHO-GMP (Good Manufacturing Practice) certification for most regulated markets, US FDA approval for exports to the United States, EU GMP certification for European markets, and country-specific regulatory approvals for markets in Africa, Asia, and Latin America. Additional certifications may include ISO 9001, Schedule M compliance under Indian drug laws, and Free Sale Certificates issued by the Central Drugs Standard Control Organization (CDSCO).

Q: How many buyers import levamisole from India?

There are 104 registered buyers importing levamisole from India, spread across 39 countries. The repeat buyer rate is 56.7%, indicating strong long-term trade relationships and consistent product quality.

Q: What is the market share of the top levamisole supplier from India?

LYKA BDR INTERNATIONAL LIMITED is the leading levamisole exporter from India with a market share of 24.7% and total export value of $658.4K across 11 shipments. The top 5 suppliers together control 66.2% of total export value.

Suresh Sormare

Levamisole

India Pharmaceutical Trade Intelligence

$2.7M72 Suppliers39 CountriesHS 30049099

ExportsIndia → SUDAN39.3%India → CONGO DR14.9%

Levamisole Export Analysis | India Pharmaceutical Trade Intelligence | TransData Nexus

How India Exports Levamisole to the World

Between 2022 and 2026, India exported $2.7M worth of levamisole across 325 verified shipments to 39 countries — covering 20% of world markets in the Antimalarial & Antiparasitic segment. The largest destination is SUDAN (39.3%). LYKA BDR INTERNATIONAL LIMITED leads with a 24.7% share. All figures are drawn from Indian Customs (DGFT) shipping bill records spanning four years of trade activity.

Source: Indian Customs (DGFT)·Published March 2026·Updated March 2026·

Levamisole export data from India — top exporters, importing countries, pricing and trade statistics compiled by TransData Nexus — Levamisole export data snapshot — $2.7M · 72 exporters · 39 countriesTransData Nexus · Indian Customs Data

Top Levamisole Exporters from India

72 active exporters · Ranked by export value

View all 72 →

Top Levamisole Exporters from India — Ranked by Export Value
#	Supplier Name	Export Value (USD)	Shipments	Countries	Market Share
1	LYKA BDR INTERNATIONAL LIMITED	$658.4K	11	2	24.7%
2	LYKA LABS LIMITED

Top Countries Importing Levamisole from India

39 destination markets · Ranked by import value

All 39 countries →

Top Countries Importing Levamisole from India — Ranked by Import Value
#	Country	Import Value (USD)	Market Share
1	SUDAN	$1.0M	39.3%
2	CONGO DR	$397.6K	14.9%
3	UZBEKISTAN	$372.7K	14.0%
4	UNITED KINGDOM	$95.5K	3.6%
5	CHAD	$82.1K	3.1%
6	UNITED ARAB EMIRATES	$81.1K	3.0%
7	AFGHANISTAN	$80.0K	3.0%
8	LIBYA	$70.2K	2.6%
9	AZERBAIJAN	$55.9K	2.1%
10	CONGO	$41.1K	1.5%

SUDAN is India's largest levamisole export destination, absorbing 39.3% of total exports worth $1.0M. The top 5 importing countries — SUDAN, CONGO DR, UZBEKISTAN, UNITED KINGDOM, CHAD — together account for 74.9% of India's total levamisole export value. The remaining 34 destination countries collectively receive the other 25.1%, indicating a focused distribution strategy targeting key markets.

Regulatory Landscape — Levamisole

Product-specific regulatory status across FDA, EMA, WHO, and CDSCO · As of March 2026

1FDA & US Market Regulatory Status

As of March 2026, the FDA's Orange Book does not list any approved Abbreviated New Drug Applications (ANDAs) for levamisole, indicating a lack of generic approvals for this compound in the United States. Additionally, there are no current import alerts or detentions related to levamisole, suggesting that the FDA has not identified significant compliance issues with this product. The absence of approved ANDAs and import alerts implies that levamisole is not actively marketed or regulated as a pharmaceutical product in the U.S. market. This context is particularly relevant given the 72 active Indian exporters of levamisole, highlighting a potential gap or opportunity in the U.S. pharmaceutical landscape.

2EU & UK Regulatory Framework

In February 2026, the European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) recommended the withdrawal of marketing authorizations for levamisole-containing medicines across the EU due to the risk of leukoencephalopathy, a serious neurological condition. This decision underscores the stringent safety evaluations conducted by EU regulatory bodies. In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) aligns with EMA decisions, suggesting a similar stance on levamisole. Compliance with EU Good Manufacturing Practice (GMP) requirements remains a prerequisite for any pharmaceutical product intended for the European market.

3WHO Essential Medicines & Global Standards

Levamisole is not listed in the current edition of the WHO Model List of Essential Medicines, indicating its limited recognition as a critical medicine globally. Furthermore, levamisole has not undergone the WHO Prequalification Programme, which assesses the quality, safety, and efficacy of medicinal products. Regarding pharmacopoeial standards, levamisole is included in the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), providing standardized quality benchmarks for its formulation and use.

4India Regulatory Classification

In India, levamisole is classified under Schedule H of the Drugs and Cosmetics Act, requiring a prescription for its dispensation. The National Pharmaceutical Pricing Authority (NPPA) has not set a ceiling price for levamisole, indicating it is not under direct price control as of March 2026. For export purposes, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) for pharmaceutical products, ensuring compliance with national and international regulatory standards.

5Patent & Exclusivity Status

Levamisole's primary patents have expired, leading to the availability of generic versions in various markets. This expiration has facilitated increased competition among manufacturers and exporters, particularly from India, which has emerged as a significant supplier of generic levamisole to multiple countries.

6Recent Industry Developments

In February 2026, the EMA's PRAC recommended the withdrawal of marketing authorizations for levamisole-containing medicines in the EU due to safety concerns, specifically the risk of leukoencephalopathy. This decision has significant implications for exporters targeting the European market. In January 2026, the FDA updated its import alerts to reinforce that all unauthorized e-cigarettes may be detained without physical examination, reflecting the agency's stringent enforcement policies. While not directly related to levamisole, this action underscores the FDA's commitment to ensuring compliance with regulatory standards for all imported products. In October 2025, the FDA announced the implementation of import certification requirements for certain food products, effective October 31, 2025. Although this pertains to food items, it highlights the FDA's proactive approach to import regulation, which could extend to pharmaceuticals in the future.

These developments underscore the dynamic nature of the global pharmaceutical regulatory landscape, necessitating continuous monitoring and compliance by exporters to maintain market access.

TransData Nexus Research · FDA Orange Book, EMA, WHO Model List, CDSCO/NPPAUpdated Mar 2026

Get Complete Export Intelligence Report

300+ pages · Supplier profiles · Buyer analysis · Price benchmarks · Every shipment record

Free

Global Price Benchmark — Levamisole

Retail & reference prices across 9 markets vs. India FOB export price of $7.36/unit

Global Price Benchmark for Levamisole across major pharmaceutical markets
Market	Price (USD/unit)	Currency	Reference
United States	Data not available	USD	Specific pricing information for Levamisole in the United States is not readily accessible through public government sources.
United Kingdom	Data not available	GBP	The UK's National Health Service (NHS) Drug Tariff does not list Levamisole, indicating limited availability or usage within the NHS framework.
Germany	Data not available	EUR	Specific pricing data for Levamisole in Germany is not publicly available through government sources.
Australia

Supply Chain Risk Assessment — Levamisole

API sourcing, concentration risk, storage requirements, and current alerts

HIGH RISK

1API Sourcing & Raw Material Dependency

India's pharmaceutical industry, including the production of Levamisole, heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) sourced from China. According to the U.S. Pharmacopeia, 41% of KSMs used in U.S.-approved APIs are solely sourced from China, while 16% come from India. This dependency poses a significant risk, as any disruption in China's supply chain can directly impact India's pharmaceutical manufacturing capabilities.

Recent geopolitical tensions have exacerbated these vulnerabilities. The closure of the Strait of Hormuz in March 2026, a critical maritime chokepoint, has disrupted global trade routes, including those essential for transporting raw materials to India. This blockade has led to increased shipping costs and delays, further straining the supply chain for Levamisole production. (lemonde.fr)

2Supplier Concentration & Single-Source Risk

Our proprietary trade data indicates that the top five Indian exporters of Levamisole account for 66.2% of total exports, with LYKA BDR INTERNATIONAL LIMITED alone holding a 24.7% share. This high supplier concentration heightens the risk of supply disruptions, as issues affecting these key players can significantly impact global availability.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme, aiming to boost domestic API production and reduce reliance on imports. However, the effectiveness of this initiative in diversifying the supplier base for Levamisole remains to be seen.

Access Complete Levamisole Trade Intelligence

Shipment-level records, verified supplier contacts, buyer histories, and pricing analytics for all 325 transactions across 39 markets.

Request Demo View Pricing

Frequently Asked Questions — Levamisole Exports from India

Data-backed answers sourced from Indian Customs shipping bill records

Who are the top levamisole exporters from India?

The leading levamisole exporters from India are LYKA BDR INTERNATIONAL LIMITED, LYKA LABS LIMITED, COMBITIC GLOBAL CAPLET PRIVATE LIMITED, and 10 others. LYKA BDR INTERNATIONAL LIMITED leads with 24.7% market share ($658.4K). The top 5 suppliers together control 66.2% of total export value.

What is the total export value of levamisole from India?

The total export value of levamisole from India is $2.7M, recorded across 325 shipments from 72 active exporters to 39 countries. The average shipment value is $8.2K.

Which countries import levamisole from India?

India exports levamisole to 39 countries. The top importing countries are SUDAN (39.3%), CONGO DR (14.9%), UZBEKISTAN (14.0%), UNITED KINGDOM (3.6%), CHAD (3.1%), which together account for 74.9% of total export value.

What is the HS code for levamisole exports from India?

The primary HS code for levamisole exports from India is 30049099. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) to track and report pharmaceutical export flows.

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Levamisole

Levamisole

How India Exports Levamisole to the World

Top Levamisole Exporters from India

Top Countries Importing Levamisole from India

Quick Facts

Related Antimalarial & Antiparasitic

Related Analysis

Need Details?

Regulatory Landscape — Levamisole

1FDA & US Market Regulatory Status

2EU & UK Regulatory Framework

3WHO Essential Medicines & Global Standards

4India Regulatory Classification

5Patent & Exclusivity Status

6Recent Industry Developments

Global Price Benchmark — Levamisole

Supply Chain Risk Assessment — Levamisole

1API Sourcing & Raw Material Dependency

2Supplier Concentration & Single-Source Risk

Access Complete Levamisole Trade Intelligence

Frequently Asked Questions — Levamisole Exports from India

Who are the top levamisole exporters from India?

What is the total export value of levamisole from India?

Which countries import levamisole from India?

What is the HS code for levamisole exports from India?

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

India Cost Advantage

3Geopolitical & Shipping Disruptions

4Risk Mitigation Recommendations

What is the average price of levamisole exports from India?

Which ports handle levamisole exports from India?

Why is India a leading exporter of levamisole?

What certifications do Indian levamisole exporters need?

How many buyers import levamisole from India?

What is the market share of the top levamisole exporter from India?

Analysis Methodology